Cariprazine Pediatric ASD PK Study

NCT04382885 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: 2000-103-009
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 3

Brief Summary

This study will be a multi-center, open-label, parallel-group, multiple-dose study in up to 24 male and female participants aged 5 through 17 years, inclusive, with Autism Spectrum Disorder (ASD). The 24 participants will be enrolled into 1 of 4 cohorts (6 participants per cohort).

Conditions

Autism Spectrum Disorder

Keywords

ASD; Autism

Outcome Measures

Primary Outcomes (18)

• Incidence of Adverse Events (AEs)

  Up to 30 days after last visit or last dose for participants who discontinue early

• Incidence of Serious Adverse Events (SAEs)

  Up to 30 days after last visit or last dose for participants who discontinue early

• Incidence of AEs leading to discontinuation

  Up to 30 days after last visit or last dose for participants who discontinue early

• Percentage of participants with potentially clinically significant values in clinical laboratory assessments

  Up to 84 days

• Percentage of participants with potentially clinically significant values in vital signs assessments

  Up to 84 days

• Percentage of participants with potentially clinically significant values in ECG assessments

  Up to 84 Days

• Percentage of participants who have suicidal ideation or suicidal behaviors in C-SSRS assessments

  Up to 84 Days

• Percentage of participants with treatment-emergent parkinsonism in SAS assessments

  Up to 84 Days

• Percentage of participants with treatment-emergent akathisia in BARS assessments

  Up to 84 days

• Percentage of participants with potentially clinically significant values in ocular examination parameters

  Screening to Day 84

• Pharmacokinetics: Maximum plasma concentrations (Cmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42

  Day 1 and Day 42

• Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42

  Day 1 and Day 42

• Pharmacokinetics: Area under the plasma concentration-time curve during the dosing interval (AUC0-tau) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42

  Day 1 and Day 42

• Pharmacokinetics: Terminal elimination half-life (T1/2) of cariprazine and its metabolites DCAR and DDCAR

  Day 42 to Day 84

• Pharmacokinetics: Minimum plasma concentrations (Cmin) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42

  Day 42

• Pharmacokinetics: Average plasma concentrations (Cavg) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42

  Day 42

• Pharmacokinetics: Apparent total clearance of cariprazine from plasma (CL/F) on Day 42

  Day 42

• Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of cariprazine

  Day 42 to Day 84

Study Arms (4)

Cohort 1 (10-17 years)

EXPERIMENTAL

10 to 12 years: 0.75 mg/day cariprazine oral solution 13 to 17 years: 1.5 mg/day cariprazine oral solution

Drug: Cariprazine

Cohort 2 (10-17 years)

EXPERIMENTAL

10 to 12 years: 1.5 mg/day cariprazine oral solution 13 to 17 years: 3.0 mg/day cariprazine oral solution

Drug: Cariprazine

Cohort 3 (5-9 years)

EXPERIMENTAL

0.5 mg/day cariprazine oral solution

Drug: Cariprazine

Cohort 4 (5-9 years)

EXPERIMENTAL

1.5 mg/day cariprazine oral solution

Drug: Cariprazine

Interventions

Cariprazine DRUG

Oral Solution

Cohort 1 (10-17 years); Cohort 2 (10-17 years); Cohort 3 (5-9 years); Cohort 4 (5-9 years)

Eligibility Criteria

• Age: 5 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Participants must meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria for ASD (Autism Spectrum Disorder) diagnosis.
• Participants must have normal physical examination findings and clinical laboratory test results for their age group or abnormal results judged not clinically significant by the investigator.
• Negative serum hCG (human chorionic gonadotropin) pregnancy test at screening (all female participants that have reached menarche).
• BMI greater than the 5th percentile for age and gender based on CDC (Centers for Disease Control and Prevention) growth charts.
• Participant (if reached his spermarche or her menarche), must agree to sexual abstinence or to use an approved birth control method for the full duration of participation in the study. The investigator and each participant will determine the appropriate method of contraception for the participant during their participation in the study.
• Participant's parent(s)/legal representative(s) must be capable of giving signed informed consent , which includes compliance with the requirements and restrictions listed in the ICF and in the protocol as explained by the investigator. Written informed consent from the participant's parent(s)/legal representative(s) must be obtained prior to any study-related procedures.
• Assent (unless local regulations require consent) must be obtained for all participants participating in the study.
• Participant must have a parent or legal representative who is willing and able to be responsible for safety monitoring of the participant, provide information about the participant's condition, oversee administration of study intervention, and accompany the participant to all study visits. The caregiver can be the participant's parent(s)/legal representative(s). Written consent from the caregiver must be obtained.

You may not qualify if:

• Current diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition.
• Diagnosis of intellectual disability (IQ \< 70) documented by school record, neuropsychological testing or medical records.
• Participant has a history of meeting DSM-5 diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before the Screening Visit.
• Participant with an acute or unstable medical condition, including (but not limited to) inadequately controlled diabetes, hepatic insufficiency (specifically any degree of jaundice), uncorrected hyper- or hypo-thyroidism, acute systemic infection, renal, gastrointestinal, respiratory, or cardiovascular disease.
• History of seizures, with the exception of febrile seizures.
• History of tumor of the central nervous system.
• Previously taken cariprazine or previously participated in an investigational study of cariprazine.
• Participant is currently enrolled in an investigational drug or device study or participation in such a study within 3 months of Study Day 1.
• Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to Study Day 1.
• Positive UDS for substances of abuse at the Screening Visit or on Study Day -1.
• Known allergy or sensitivity to the study intervention or its components.

Sponsors & Collaborators

• AbbVie: lead

Study Sites (3)

Neuropsychiatric Research Center of Orange County /ID# 233663

Orange, California, 92868, United States

Location

Atlanta Center for Medical Research /ID# 233576

Atlanta, Georgia, 30331, United States

Location

iResearch Atlanta, LLC /ID# 233614

Decatur, Georgia, 30030, United States

Location

Related Links

• Additional information on study locations near you may be found at AllerganClinicalTrials.com.
• To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.

MeSH Terms

Conditions

Autism Spectrum Disorder; Autistic Disorder

Interventions

cariprazine

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders

Study Officials

• ALLERGAN INC.

  Allergan

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 19, 2020
• First Posted: May 11, 2020
• Study Start: June 26, 2020
• Primary Completion: December 10, 2021
• Study Completion: December 10, 2021
• Last Updated: April 12, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)